Table S1.

Data of cases and controls

Variable	Control group (N=9070)		HCC group (N=9070)		p-value
	n	%	n	%
SSRI drug used
No	8691	95.82	8803	97.06	<0.0001
Yes	379	4.18	267	2.94
<28 cDDD	117	1.29	98	1.08
28–89 cDDD	102	1.12	65	0.72
90–364 cDDD	88	0.97	55	0.61
≥365 cDDD	72	0.79	49	0.54
Sex					0.99
Female	2039	22.48	2039	22.48
Male	7031	77.52	7031	77.52
Age, years (SD)#	53.12 (12.45)		53.42 (12.53)		0.1456
20–29 years	192	2.12	192	2.12	0.99
30–39 years	969	10.68	969	10.68
40–49 years	2798	30.85	2798	30.85
50–59 years	2610	28.78	2610	28.78
≥60 years	2501	27.57	2501	27.57
Comorbidity
Alcohol-related disease	356	3.93	1181	13.02	<0.0001
Cirrhosis	598	6.59	5997	66.12	<0.0001
NAFLD	475	5.24	337	3.72	<0.0001
Hypertension	3242	35.74	2942	32.44	<0.0001
Hyperlipidemia	2655	29.27	1518	16.74	<0.0001
Biliary stones	647	7.13	916	10.1	<0.0001
CKD	598	6.59	857	9.45	<0.0001
Diabetes	1826	20.13	2085	22.99	<0.0001
CHF	263	2.90	340	3.75	<0.0001
COPD	1742	19.21	1101	12.14	<0.0001
Anti-viral drugs
No	8836	97.42	7975	87.93	<0.0001
Yes	234	2.58	1095	12.07
Statin
No	7677	84.64	8067	88.94	<0.0001
Yes	1393	15.36	1003	11.06
Metformin
No	424	4.67	189	2.08	<0.0001
Yes	8646	95.33	8881	97.92

Notes: Chi-square test;

^#2-sample t-test.

Abbreviations: cDDD, cumulative defined daily dose; CHF, congestive heart failure; CKD, chronic kidney disease; HCC, hepatocellular carcinoma; NAFLD, nonalcoholic fatty liver disease; SSRI, selective serotonin reuptake inhibitor.